Phase 3 Psoriasis Trial, Recruiting NCT06842199 Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Condition: Psoriasis
Back to Psoriasis

Phase 3 Psoriasis Trial, Recruiting

NCT06842199
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have agreed to take part voluntarily and have signed a consent form
  • People aged 18 to 75 years old at the time of signing the consent form
  • People who have had plaque psoriasis for at least 6 months before the start of the study
  • People whose psoriasis requires whole-body (systemic) treatment and/or light therapy (phototherapy)
  • People whose psoriasis meets all three of these severity measures: a PASI score of 12 or higher, psoriasis covering 10% or more of the body surface area, and a doctor's overall severity rating (sPGA) of 3 or higher

Who may not be able to join:

  • People whose psoriasis is a type other than plaque psoriasis
  • People who have another skin condition that the study doctor believes could interfere with assessments
  • People who have an active infection or an immune system disease
  • People who have a history of tuberculosis (TB) or are considered at risk of TB
  • People who have recently received certain treatments within timeframes set out in the study rules (confirm with trial site)
  • People who have recently taken, or plan to take during the study, certain medications that strongly affect the way the body processes some drugs (known as strong CYP1A2/CYP3A4 inhibitors or inducers) — specific timing rules apply (confirm with trial site)
  • People whose test or laboratory results during the screening period show findings that the study doctor considers a significant health risk for participation
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study
  • People with a history of severe allergic reactions to medicines
  • People the study doctor considers unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 010-66609745

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Registry
ClinicalTrials.gov
Start date
20 March 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The proportion of subjects who achieve a score of clear (0) or almost clear (1) with an improvement of at least 2 points from baseline on the static Physician's Global Assessment (sPGA) at week 16; Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 16

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov